NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Natalizumab and Chronic Inflammation

TerminatedPhase 4

Sponsor: Vanderbilt University Medical Center

Conditions: Multiple Sclerosis

Interventions: Natalizumab 300 MG in 15 ML Injection

Countries: United States

In this study the investigators will assess the ability of Natalizumab, a medication given to treat multiple sclerosis (MS), to restore blood brain barrier integrity and repair subtle leakages of the blood brain barrier (BBB).

Eligibility overview

Sex: ALL

Age: 18 Years to 65 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

1. multiple sclerosis
2. clinical eligibility to treatment with Natalizumab
3. no previous exposure to Natalizumab treatment

Exclusion Criteria:

1. inability to perform an MRI with contrast
2. inability to undergo a paper-pencil questionnaires and blood work

Locations (1)

Nashville, Tennessee, United States